Osiris Therapeutics, Inc.
(NASDAQ: OSIR) announced today the passing of one of its Board Members, Gregory H. Barnhill. Mr. Barnhill has served on Osiris’ Board of Directors since the company went public in August of 2006 and was a member of the Audit, Nominating and Compensation Committees.
“Greg was not only a good friend, but a trusted advisor and dedicated board member,” said Peter Friedli, Chairman and Co-founder of Osiris Therapeutics. “He will be missed. On behalf of the entire organization, I extend our deepest sympathies to his family in this time of sorrow.”
The Board of Directors held a Special Meeting on September 19
, 2012, and upon recommendation of the Nominating Committee, elected Hans Klingemann, M.D., Ph.D. to the position of Director. Dr. Klingemann joins Osiris as an independent Board Member and, given his qualifications, has been appointed to serve as a member of the company’s Audit, Compensation and Nominating Committees. He will fill the term as a Class I Director until its expiration at the 2013 Annual Meeting of Stockholders, or until another successor is duly elected and qualified.
Dr. Klingemann is the Director of the Bone Marrow and Stem Cell Transplant Program at Tufts Medical Center in Boston, and a Professor of Medicine at Tufts University Medical School. He also directs the Hematological Malignancies Program at the Tufts Medical Center Cancer Center and runs a stem cell transplant research laboratory. Previously, Dr. Klingemann was director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center, and founding director of the Sramek Center for Cell Engineering in Chicago, Illinois. He has worked as a physician, scientist, educator and administrator in leadership positions for over twenty years at various academic medical centers and has authored over 150 scientific and medical papers.
About Osiris Therapeutics
Osiris Therapeutics, Inc., having developed the world’s first approved stem cell drug, Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix® for burns and chronic wounds, and Ovation® for orthopedic applications. Osiris is a fully integrated company with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 48 U.S. and 144 foreign patents.